Yu Zhou

发表

The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020

Yuankai Shi, Xiaohong Han, Liling Huang, 2021, The Lancet regional health. Western Pacific.

Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients

P. Xing, Yuankai Shi, Dan Wang, 2020, Theranostics.

A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma

P. Liu, Jian-liang Yang, Sheng Yang, 2022, Asia-Pacific journal of clinical oncology.

Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era

P. Liu, Jian-liang Yang, Sheng Yang, 2022, BMC cancer.

Long‐term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single‐center retrospective study

Yuankai Shi, P. Liu, Jian-liang Yang, 2020, Asia-Pacific journal of clinical oncology.

Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis

Yu Feng, Y. Tao, Haizhu Chen, 2022, Cancer Immunology, Immunotherapy.

Low CCL19 Expression Is Associated With Adverse Clinical Outcomes For Patients With Advanced Stage Follicular Lymphoma

N. Lou, P. Liu, Yuankai Shi, 2021 .

The clinical features, treatment, and prognostic factors for peripheral T‐cell lymphomas: A single‐institution analysis of 240 Chinese patients

P. Liu, Jian-liang Yang, Sheng Yang, 2022, Asia-Pacific journal of clinical oncology.

Prognostic role of red blood cell distribution width and platelet/lymphocyte ratio in early-stage classical Hodgkin lymphoma.

P. Liu, Jian-liang Yang, Sheng Yang, 2022, Future oncology.

Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy

N. Lou, P. Xing, Yuankai Shi, 2021, Cancer Immunology, Immunotherapy.

Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis

Yu Feng, Y. Tao, Haizhu Chen, 2022, Investigational New Drugs.

Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis

Yuankai Shi, Daquan Wang, Q. Zhong, 2020, Cancer Immunology, Immunotherapy.

R‐CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B‐cell lymphoma

Yuankai Shi, P. Liu, Xin Wang, 2020, Asia-Pacific journal of clinical oncology.

Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy

N. Lou, P. Liu, Yuankai Shi, 2021, Journal of Translational Medicine.

Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis

Yuankai Shi, Q. Zhong, Y. Tao, 2021, Journal of Cancer.

Incidence, Survival Outcome, and Prognostic Nomogram of Patients with Angioimmunoblastic T-cell Lymphoma: a Population-based Analysis

Yuankai Shi, Q. Zhong, Y. Tao, 2022, Current Medical Science.

Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Yu Feng, Liling Huang, Y. Tao, 2023, Immunotherapy.

The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005–2020): A systematic review

Yuankai Shi, Xiaohong Han, Haizhu Chen, 2021, The Lancet regional health. Western Pacific.

Meta-analysis of the prognostic and clinical value of serum 25-hydroxyvitamin D levels in previously untreated lymphoma.

Yuankai Shi, Y. Tao, Haizhu Chen, 2021, Future oncology.

Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma

Xiaobo Yu, Guibin Wang, Q. Zhong, 2023, Molecular & cellular proteomics : MCP.

Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis

Xingsheng Hu, Yu Feng, Y. Tao, 2023, Thoracic cancer.

Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study

Jian-liang Yang, Shengyu Zhou, Q. Zhong, 2023, Annals of hematology.